{"organizations": [], "uuid": "92d84bfc34fa6308d37b063a35681fc462f534a6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-momenta-pharmaceuticals-reports-q4/brief-momenta-pharmaceuticals-reports-q4-earnings-per-share-0-18-idUSASB0C6NM", "country": "US", "domain_rank": 408, "title": "BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T15:21:00.000+02:00", "replies_count": 0, "uuid": "92d84bfc34fa6308d37b063a35681fc462f534a6"}, "author": "", "url": "https://www.reuters.com/article/brief-momenta-pharmaceuticals-reports-q4/brief-momenta-pharmaceuticals-reports-q4-earnings-per-share-0-18-idUSASB0C6NM", "ord_in_thread": 0, "title": "BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-momenta pharmaceuticals reports", "sentiment": "negative"}, {"name": "momenta pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "momenta pharmaceuticals", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 1:21 PM / Updated 11 minutes ago BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18 Reuters Staff Feb 21 (Reuters) - Momenta Pharmaceuticals Inc: * MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * Q4 REVENUE $64.6 MILLION VERSUS $34.2 MILLION * Q4 EARNINGS PER SHARE $0.18 * ‍NET INCOME IN 2017 PERIOD WAS DRIVEN BY RECOGNITION OF $50.0 MILLION UPFRONT PAYMENT FROM CSL AS REVENUE​ * Q4 EARNINGS PER SHARE VIEW $-0.31, REVENUE VIEW $66.6 MILLION -- THOMSON REUTERS I/B/E/S * MOMENTA PHARMACEUTICALS - SEES ‍NON-GAAP OPERATING EXPENSE OF ABOUT $180 MILLION - $220 MILLION FOR 2018 AND $45 MILLION - $55 MILLION FOR Q1 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T15:21:00.000+02:00", "crawled": "2018-02-21T15:40:03.006+02:00", "highlightTitle": ""}